Harrow Health Inc (HROW)vsUnited Therapeutics Corporation (UTHR)
HROW
Harrow Health Inc
$29.37
-3.64%
HEALTHCARE · Cap: $1.10B
UTHR
United Therapeutics Corporation
$593.31
-0.39%
HEALTHCARE · Cap: $25.07B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 951% more annual revenue ($3.19B vs $303.25M). UTHR leads profitability with a 38.6% profit margin vs -9.4%. UTHR earns a higher WallStSmart Score of 55/100 (C).
HROW
Hold40
out of 100
Grade: F
UTHR
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HROW.
Margin of Safety
+2.4%
Fair Value
$487.71
Current Price
$593.31
$105.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 38.6% year-over-year
Earnings expanding 810.0% YoY
Keeps 39 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.0%
Areas to Watch
Smaller company, higher risk/reward
Trading at 38.1x book value
ROE of -35.4% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
4.1% revenue growth
Earnings declined 20.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : HROW
The strongest argument for HROW centers on Revenue Growth, EPS Growth. Revenue growth of 38.6% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Altman Z-Score, Operating Margin. Profitability is solid with margins at 38.6% and operating margin at 29.0%.
Bear Case : HROW
The primary concerns for HROW are Market Cap, Price/Book, Return on Equity. Debt-to-equity of 19.79 is elevated, increasing financial risk.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
HROW profiles as a hypergrowth stock while UTHR is a value play — different risk/reward profiles.
UTHR carries more volatility with a beta of 0.48 — expect wider price swings.
HROW is growing revenue faster at 38.6% — sustainability is the question.
UTHR generates stronger free cash flow (126M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (55/100 vs 40/100), backed by strong 38.6% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Harrow Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?